Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Crestline Management, LP (CIK 1536054) reported $46.3M across 3 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: DNLI ($42.4M, 91.74%), SANA ($2.2M, 4.70%), EGHT ($1.6M, 3.56%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | DNLI | DENALI THERAPEUTICS INC | $42.4M | 91.74% | 2.2M | Trimmed |
| 2 | SANA | SANA BIOTECHNOLOGY INC | $2.2M | 4.70% | 755,736 | Trimmed |
| 3 | EGHT | 8X8 INC NEW | $1.6M | 3.56% | 990,850 | Added |
Source: SEC Form 13F filings · as of 2026-03-31